© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Aug 29, 2015, the consensus forecast amongst 2 polled investment analysts covering GW Pharmaceuticals plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Jun 25, 2015. The previous consensus forecast advised investors to hold their position in GW Pharmaceuticals plc.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 2 analysts offering 12 month price targets for GW Pharmaceuticals plc have a median target of 332.50, with a high estimate of 530.00 and a low estimate of 135.00. The median estimate represents a -44.21 % decrease from the last price of 596.00. View Full Financials
Dividend information is not available for GW Pharmaceuticals PLC. View Full Financials
On Aug 06, 2015, GW Pharmaceuticals plc reported 3rd quarter 2015 losses of -0.085 per share. This result under-performed the breakeven expectation of the one analyst following the company but exceeded last year's 3rd quarter results by -0.053.
The next earnings announcement is expected on Nov 30, 2015. View Full Interim Financials
|Average growth rate||-147.10 %|
GW Pharmaceuticals plc reported annual 2014 losses of -0.070 per share on Dec 02, 2014.
The next earnings announcement from GW Pharmaceuticals plc is expected the week of Nov 30, 2015. View Full Annual Financials
|Average growth rate||-61.50 %|
GW Pharmaceuticals plc had 3rd quarter 2015 revenues of 8.63m. This missed the 13.00m estimate of the one analyst following the company. This was 13.38% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+5.24 %|
GW Pharmaceuticals plc had revenues for the full year 2014 of 30.05m. This was 10.08% above the prior year's results. View Full Annual Financials
|Average growth rate||+0.21 %|